China National Medicines' falling ROCE and high dependence o...

China National Medicines' falling ROCE and high dependence on short-term creditors could worry potential investors. The modest 32% stock gain over five years may reflect these concerns. The firm's reinvestment despite declining returns may not bode well for multi-bagger investors.